中红医疗
(300981)
| 流通市值：53.14亿 | | | 总市值：57.98亿 |
| 流通股本：3.93亿 | | | 总股本：4.29亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,863,658,896.34 | 1,237,534,880.54 | 629,149,972.58 | 2,456,650,714.86 |
| 营业收入 | 1,863,658,896.34 | 1,237,534,880.54 | 629,149,972.58 | 2,456,650,714.86 |
| 二、营业总成本 | 1,889,367,380.39 | 1,238,841,258.3 | 611,325,794.71 | 2,368,710,307.73 |
| 营业成本 | 1,667,274,550 | 1,096,943,901.11 | 545,104,981.95 | 2,128,183,526.9 |
| 税金及附加 | 18,636,121.65 | 12,437,666.35 | 5,864,876.77 | 19,187,352.34 |
| 销售费用 | 89,732,911.66 | 61,250,919.04 | 28,905,695.56 | 117,057,879.84 |
| 管理费用 | 94,210,090.48 | 62,437,866.29 | 29,593,781.35 | 126,638,932.82 |
| 研发费用 | 37,187,779.66 | 23,972,004.69 | 11,499,945.08 | 49,703,810.59 |
| 财务费用 | -17,674,073.06 | -18,201,099.18 | -9,643,486 | -72,061,194.76 |
| 其中:利息费用 | 21,495,355.03 | 12,267,763.22 | 5,586,848.87 | 24,090,843.34 |
| 其中:利息收入 | 39,920,495.01 | 29,864,341.96 | 13,831,802.96 | 67,846,377.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 26,062,737.81 | 20,347,303.14 | 6,910,640.29 | 48,107,894.49 |
| 加:投资收益 | 8,761,768.44 | 4,229,774.75 | 963,156.71 | 11,020,084.83 |
| 净敞口套期收益 | - | 0 | - | 0 |
| 资产处置收益 | -792,071.2 | -792,071.2 | -2,761.06 | 852,573.04 |
| 资产减值损失(新) | -25,099,406.45 | -17,222,220.49 | -3,912,942.94 | -228,888,328 |
| 信用减值损失(新) | -2,511,375.33 | -5,093,642.09 | -456,307.24 | -5,062,697.93 |
| 其他收益 | 8,851,857.94 | 4,987,971.08 | 1,348,556.76 | 20,292,700.71 |
| 四、营业利润 | -10,434,972.84 | 5,150,737.43 | 22,674,520.39 | -65,737,365.73 |
| 加:营业外收入 | 2,083,617.67 | 1,801,029.8 | 577,008.37 | 1,126,657.52 |
| 减:营业外支出 | 820,260.04 | 789,290.38 | 180,731.04 | 2,292,734.6 |
| 五、利润总额 | -9,171,615.21 | 6,162,476.85 | 23,070,797.72 | -66,903,442.81 |
| 减:所得税费用 | 392,118.66 | 1,984,183.2 | 3,723,636.47 | 18,926,992.5 |
| 六、净利润 | -9,563,733.87 | 4,178,293.65 | 19,347,161.25 | -85,830,435.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -9,563,733.87 | 4,178,293.65 | 19,347,161.25 | -85,830,435.31 |
| 终止经营净利润 | - | 0 | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -7,210,152.72 | 5,742,934.2 | 18,921,091.71 | -87,128,895.94 |
| 少数股东损益 | -2,353,581.15 | -1,564,640.55 | 426,069.54 | 1,298,460.63 |
| 扣除非经常损益后的净利润 | -37,344,922.5 | -13,174,490.58 | 11,371,210.65 | -143,463,298.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | 0.01 | 0.05 | -0.22 |
| (二)稀释每股收益 | -0.02 | 0.01 | 0.05 | -0.22 |
| 八、其他综合收益 | -1,059,948.56 | -635,986.53 | -253,697.08 | -2,540,792.49 |
| 归属于母公司股东的其他综合收益 | -1,035,403.26 | -635,986.53 | -253,697.08 | -2,540,792.49 |
| 九、综合收益总额 | -10,623,682.43 | 3,542,307.12 | 19,093,464.17 | -88,371,227.8 |
| 归属于母公司股东的综合收益总额 | -8,245,555.98 | 5,106,947.67 | 18,667,394.63 | -89,669,688.43 |
| 归属于少数股东的综合收益总额 | -2,378,126.45 | -1,564,640.55 | 426,069.54 | 1,298,460.63 |
| 公告日期 | 2025-10-29 | 2025-08-28 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |